A donor-specific antibody test looks for antibodies that recognize human leukocyte antigen, or HLA, markers carried by a particular organ or stem-cell donor. These antibodies matter because they can attach to donor tissue, activate inflammation, and raise the risk of antibody-mediated rejection or graft failure. A positive result does not prove that rejection is occurring, and a negative result does not guarantee a complication-free transplant. Interpretation depends on when the antibody appeared, which HLA target it recognizes, its measured strength, whether it can activate complement, the type of transplant, and the condition of the graft. Testing may be performed before transplantation to judge donor compatibility, after transplantation as part of surveillance, or when organ function worsens. The most useful report connects antibody findings with donor HLA typing, crossmatch results, prior sensitizing events, medication adherence, laboratory trends, imaging, and—when needed—a biopsy.
- A DSA is an antibody directed against an HLA marker present in the specific donor.
- A positive DSA result signals immunologic risk, but it does not diagnose rejection by itself.
- Preformed DSA exists before transplant; de novo DSA develops after transplant.
- MFI is a semi-quantitative laboratory signal, not a universal antibody concentration or fixed danger cutoff.
- Rising DSA plus declining graft function usually needs prompt transplant-team review and often further testing.
Table of Contents
- What the DSA Test Detects
- Why and When DSA Testing Is Ordered
- How the Test Is Performed
- Understanding Positive, Negative, and Changing Results
- Antibody Strength, MFI, Complement, and Other Details
- How DSA Relates to Rejection and Graft Outcomes
- Limitations and Causes of Misleading Results
- Next Steps After a DSA Result
What the DSA Test Detects
The immune system uses antibodies to recognize targets that appear foreign. In transplantation, the most important targets are often HLA molecules. HLA proteins sit on the surface of most cells and help the immune system distinguish the body’s own tissues from outside material. Because HLA genes are highly variable, a donor and recipient commonly carry different HLA markers.
A person can form anti-HLA antibodies after exposure to genetically different human cells. Common sensitizing events include:
- Pregnancy, including miscarriage or delivery
- Blood or platelet transfusion
- A previous organ, tissue, or stem-cell transplant
- Less commonly, certain cellular products or immune treatments
An HLA antibody becomes donor-specific when its target is present in the actual donor. For example, a recipient may have an antibody against HLA-DQ7. It is a DSA only if the donor carries HLA-DQ7. The same antibody is not donor-specific for a donor who lacks that marker.
This distinction explains why a general HLA antibody test and a DSA assessment are related but not identical. The antibody test identifies the recipient’s antibody specificities. Donor HLA typing supplies the donor’s antigen profile. The laboratory compares the two datasets to determine whether any antibodies are donor-specific.
DSA may target HLA class I molecules, mainly HLA-A, HLA-B, and HLA-C, or class II molecules, mainly HLA-DR, HLA-DQ, and HLA-DP. Class I targets are found on most nucleated cells and platelets. Class II expression is concentrated on antigen-presenting immune cells but can increase on blood-vessel lining cells during inflammation. Both classes can be clinically important.
Some reports also discuss antibodies against non-HLA targets. These may contribute to graft injury in selected cases, but they are not included in the usual definition of anti-HLA DSA and are not measured by every laboratory.
Why and When DSA Testing Is Ordered
DSA testing serves different purposes before and after transplantation. The timing changes what the result means.
Before an organ transplant
Before transplantation, the test helps estimate whether the recipient already has antibodies that could attack a proposed donor. These are called preformed DSA. A strong preformed antibody can produce a positive physical or virtual crossmatch and may make transplantation unsafe without additional evaluation or risk-reduction treatment.
Testing is especially important for people with prior pregnancies, transfusions, or transplants; for candidates with a high calculated panel-reactive antibody level; and for anyone whose antibody profile has changed. The DSA assessment complements the transplant crossmatch. A crossmatch asks whether recipient serum reacts with donor cells, while DSA testing identifies the likely HLA target of that reaction.
After an organ transplant
After transplantation, testing may be ordered on a planned schedule or because graft function changes. Centers differ in their surveillance protocols. Common testing points include the early months after transplant, around annual follow-up, after a reduction in immunosuppression, following suspected nonadherence, and when laboratory or imaging findings suggest graft injury.
Post-transplant DSA falls into two broad groups:
- Persistent or recurrent preformed DSA, which was known before transplant
- De novo DSA, which appears for the first time after transplant
De novo DSA often indicates that the recipient’s immune system has developed a new response to the graft. It may follow low immunosuppressant exposure, missed doses, medication interactions, infection-related immune activation, or a high degree of HLA mismatch. In many patients, no single trigger is obvious.
Before stem-cell transplantation
In allogeneic hematopoietic stem-cell transplantation, recipient DSA against mismatched donor HLA can interfere with donor-cell engraftment. This is especially relevant in haploidentical, cord-blood, and other HLA-mismatched transplants. A positive DSA may lead the team to choose another donor, repeat testing, or use a desensitization strategy before conditioning.
When symptoms or graft tests change
DSA may be checked when kidney creatinine rises, urine protein increases, liver enzymes become abnormal, heart function declines, lung function falls, or another organ-specific marker worsens. It may also be ordered after a biopsy shows microvascular inflammation or other features that could represent antibody-mediated rejection.
Urgent symptoms depend on the transplanted organ. Reduced urine output, severe shortness of breath, chest pain, jaundice, fever, rapid swelling, or a sudden change in graft function requires immediate contact with the transplant team rather than waiting for an antibody result.
How the Test Is Performed
The DSA test usually requires a blood sample from the recipient. Fasting is not normally needed. The laboratory separates serum, which contains antibodies, and tests it against HLA-coated particles or cells.
Most modern laboratories use solid-phase assays. A common method is the single-antigen bead assay. Each microscopic bead is coated with a particular HLA protein. If an antibody binds to that bead, a fluorescent detection system produces a signal. Software then identifies the HLA specificity and reports a measurement commonly called mean fluorescence intensity, or MFI.
The basic workflow is:
- Obtain a current recipient serum sample.
- Screen for anti-HLA antibodies.
- Identify individual HLA antibody specificities.
- Review the donor’s HLA type.
- Match recipient antibody targets with donor HLA markers.
- Classify matching antibodies as donor-specific.
- Integrate the findings with crossmatch and clinical information.
The donor’s HLA data must be accurate enough for the comparison. Standard HLA typing may include different loci and different levels of resolution depending on the transplant program. If the donor is typed only at a broad antigen level but the antibody reacts with a specific allele or epitope, additional typing may be required.
A physical crossmatch may be performed alongside DSA analysis. Flow-cytometry crossmatch detects recipient antibody binding to donor T cells and B cells. Complement-dependent cytotoxicity crossmatch looks for antibody-mediated cell killing. A virtual crossmatch predicts compatibility by comparing donor HLA typing with the recipient’s antibody profile without mixing the actual cells and serum.
The sample date matters. Antibodies may change after transfusion, pregnancy, transplantation, infection, or immune treatment. Programs commonly keep several historical samples because an antibody that is currently weak or undetectable may still represent immune memory. Some decisions therefore use the highest historical finding rather than only the newest result.
Certain therapies can affect testing. Intravenous immunoglobulin, plasma exchange, rituximab, anti-CD38 drugs, complement inhibitors, and other desensitization or rejection treatments may change antibody levels or interfere with assays. The laboratory and transplant team should know the treatment dates.
Understanding Positive, Negative, and Changing Results
A DSA report should be read as a pattern, not as a single positive-or-negative label. The most informative interpretation includes the target, class, timing, strength, trend, and relation to graft findings.
Negative result
A negative result means the assay did not detect a donor-specific anti-HLA antibody above the laboratory’s reporting threshold in the tested sample. Before transplant, this generally lowers concern for antibody-mediated incompatibility. After transplant, it makes current HLA DSA-related injury less likely but does not exclude rejection.
A negative result has limits. Antibody may be below detection, directed against an HLA target not included or not fully represented on the assay, hidden by technical interference, or present mainly in the graft rather than circulating at a detectable level. Antibody-mediated injury can also occur without detectable DSA, and rejection can be driven by T cells rather than antibodies.
Positive preformed DSA
A positive result before transplant means the recipient has an antibody against an HLA marker carried by the donor. Risk varies widely. A low-level antibody with a negative flow crossmatch may be handled differently from a strong antibody that produces a positive complement-dependent cytotoxicity crossmatch.
The team may label the donor HLA as an unacceptable antigen, decline that donor, pursue paired exchange, select another stem-cell donor, or consider desensitization. The choice depends on transplant urgency, organ type, waiting-time consequences, antibody characteristics, and local outcomes.
Positive de novo DSA
A newly detected DSA after transplant deserves review even when graft function appears stable. De novo DSA—especially against HLA-DQ—is associated with a higher risk of later antibody-mediated injury and graft loss. However, some antibodies remain stable without immediate measurable damage.
The result should trigger a check of medication adherence, immunosuppressant trough levels, dosing, drug interactions, recent illness, and organ-specific function. Many kidney programs consider biopsy when de novo DSA appears because normal creatinine can coexist with microscopic injury.
Persistent, falling, or disappearing DSA
A persistent antibody remains detectable on repeated testing. Persistence can carry more concern than a brief, low-level finding, particularly if the signal rises or graft tests worsen. A falling result after treatment may be encouraging, but a lower MFI does not prove that tissue injury has stopped.
An antibody may become undetectable because immune activity truly decreased, because treatment removed circulating antibody, or because the level fell below the assay threshold. Long-lived plasma cells and memory B cells may still remain. Historical DSA therefore continues to influence risk assessment.
Rising DSA
A meaningful rise is more concerning when it is reproducible, occurs with worsening organ function, or is accompanied by a positive crossmatch, complement-binding activity, or biopsy evidence of microvascular inflammation. Small changes between nearby values may reflect assay variability rather than biology.
There is no universal percentage increase that defines danger in every laboratory. The same sample may generate different MFI values on different platforms or runs. Clinicians look for a consistent trend under comparable conditions.
Antibody Strength, MFI, Complement, and Other Details
MFI is often the most visible number on a DSA report, but it is commonly misunderstood. It is a fluorescence signal generated by the assay, not a direct measurement such as milligrams per deciliter. A value of 8,000 is not necessarily twice as much antibody as a value of 4,000, and thresholds differ among laboratories and transplant types.
Broadly, higher and persistent signals tend to raise concern, but no single MFI cutoff reliably separates harmless from harmful DSA. Some centers use operational categories such as low, moderate, or strong. These categories support local decisions but should not be treated as universal standards.
Several features modify interpretation:
- HLA target: DQ, DR, DP, A, B, and C antibodies may have different clinical contexts.
- Immunoglobulin subclass: IgG3 and some other subclasses may be more inflammatory in certain settings.
- Complement binding: C1q- or C3d-binding assays assess whether an antibody can activate parts of the complement cascade.
- Titer: Testing serial dilutions can show how far antibody activity persists as serum is diluted.
- Breadth: One isolated DSA differs from several antibodies against multiple donor HLA targets.
- Persistence: Repeated detection over time is generally more concerning than a transient finding.
- Crossmatch correlation: A positive cell-based crossmatch can indicate that antibody binds donor cells under the test conditions.
- Graft findings: Function, protein leakage, donor-derived cell-free DNA, imaging, and biopsy can reveal whether injury is occurring.
Complement-binding DSA is often associated with poorer outcomes in groups of transplant recipients, but it is not a stand-alone diagnosis. Complement assays are affected by antibody concentration and technical conditions. A non-complement-binding antibody can still cause injury through cell activation, natural killer cells, or other pathways.
The prozone effect is another important issue. Very high antibody levels or complement components can paradoxically reduce the measured bead signal, making a strong antibody appear weaker. Serum dilution or chemical treatment can uncover this interference. Conversely, denatured HLA proteins on beads may expose artificial targets that do not behave the same way on living donor cells.
A high-resolution donor match can refine the assessment. Two people may share a broad antigen label but carry different alleles and surface structures. Epitope or eplet analysis examines smaller antibody-accessible features on HLA molecules. These tools can help explain antibody patterns, but they supplement rather than replace validated antibody testing and clinical judgment.
How DSA Relates to Rejection and Graft Outcomes
DSA can injure a graft when antibody attaches to donor HLA on blood-vessel lining cells. This binding may activate complement, recruit inflammatory cells, stimulate natural killer cells, and alter endothelial function. Over time, repeated microvascular injury can produce scarring and loss of graft function.
In solid-organ transplantation, the main concern is antibody-mediated rejection, also called AMR or ABMR. Diagnosis usually requires more than DSA. Depending on the organ and current criteria, clinicians combine evidence of graft dysfunction or tissue injury, characteristic biopsy changes, and signs that antibodies are interacting with the graft.
In kidney transplantation, biopsy may show glomerulitis, peritubular capillaritis, transplant glomerulopathy, C4d deposition, or compatible molecular signals. DSA supports the diagnosis but cannot replace pathology. A patient can have DSA without biopsy-proven rejection, and a biopsy can show antibody-like injury even when circulating DSA is not found.
Preformed DSA can cause hyperacute or early acute rejection when strong antibody is already present at transplantation. Modern screening and crossmatching make hyperacute rejection uncommon. Lower-level preformed DSA may instead increase the probability of early or later AMR.
De novo DSA is often linked to chronic active antibody-mediated injury. It may emerge months or years after transplantation. HLA class II antibodies, particularly HLA-DQ DSA, are frequent in this setting. Risk rises when DSA persists, strengthens, binds complement, or occurs with inadequate immunosuppressant exposure.
For heart, lung, liver, pancreas, and other organs, the clinical consequences and surveillance strategies differ. Lung recipients may develop chronic lung allograft dysfunction; heart recipients may develop cardiac allograft vasculopathy; liver recipients may tolerate some antibodies that would be more concerning in another organ. Transplant-specific expertise is essential.
In stem-cell transplantation, recipient DSA can attack donor hematopoietic cells and increase the risk of delayed engraftment or graft failure. This is biologically different from rejection of a solid organ, but the central issue is similar: recipient antibody recognizes donor HLA.
DSA is a risk marker, not destiny. Some recipients with DSA maintain good function for years, while others develop rapid injury. The combination of antibody biology, donor-recipient mismatch, immunosuppression, organ resilience, and individual immune response determines the outcome.
Limitations and Causes of Misleading Results
DSA assays are sensitive, but sensitivity creates interpretive challenges. A laboratory can detect antibodies that may never bind meaningfully to the donor graft. Results may also differ across platforms, reagent lots, thresholds, and sample treatments.
Common limitations include:
- Incomplete donor typing, especially at HLA-C, DQ, DP, or allele level
- Antibody against a shared epitope that reacts with several beads
- Denatured HLA on beads producing clinically irrelevant binding
- Prozone or other interference causing a falsely low signal
- Nonspecific background fluorescence
- Recent immunoglobulin therapy or antibody-targeting treatment
- Different cutoff rules between laboratories
- Failure to test a sufficiently recent serum sample
- Small run-to-run MFI changes that look like a biological trend
A DSA result can also be “positive” because of an assigned threshold that is appropriate for screening but too simple for final clinical decisions. The laboratory may review raw bead patterns, background, epitope relationships, serum dilution, and crossmatch findings before calling an antibody clinically important.
Not all HLA proteins are displayed equally on every tissue. An antibody target may be highly expressed on one organ or cell type and less available on another. Inflammation can increase HLA expression. These differences help explain why the same laboratory result may carry different risk in kidney, heart, liver, lung, or stem-cell transplantation.
MFI should not be compared casually across laboratories. A patient whose testing moves to a new center may need a fresh baseline. Even within one center, results are best interpreted in the context of the laboratory’s validation, cutoff, controls, and testing method.
A positive DSA test does not identify the cause of graft dysfunction by itself. Infection, medication toxicity, dehydration, recurrent disease, vascular complications, obstruction, and T-cell-mediated rejection can produce similar clinical changes. Conversely, stable routine blood tests do not always exclude microscopic antibody injury.
Next Steps After a DSA Result
The next step should match the transplant stage and the entire clinical picture. Ask the transplant team for an interpretation that addresses the donor target, antibody trend, assay method, crossmatch, and graft findings.
Before transplantation, useful questions include:
- Is the antibody definitely donor-specific?
- Is it current, historical, or both?
- What HLA locus and allele does it target?
- What are the MFI, titer, and complement findings?
- Is the flow or cytotoxic crossmatch positive?
- Does the center classify the donor HLA as unacceptable?
- Would a different donor, paired exchange, or desensitization reduce risk?
- How does waiting compare with proceeding under a higher-risk protocol?
After transplantation, the team commonly reviews medication use first. Missed doses should be discussed honestly; the purpose is to protect the graft, not assign blame. Clinicians may check tacrolimus, cyclosporine, sirolimus, or other drug levels; review interactions; and correct underexposure when safe.
Additional testing may include repeated DSA under comparable laboratory conditions, a physical crossmatch, donor-derived cell-free DNA, organ-function tests, urine protein, imaging, or biopsy. A biopsy is often the most direct way to determine whether tissue injury is present and what type of rejection or nonimmune problem is occurring.
Treatment is not based on DSA alone. A stable patient with a newly detected low-level antibody may receive closer observation and optimization of maintenance immunosuppression. Biopsy-proven active AMR may lead to combinations of plasma exchange, intravenous immunoglobulin, corticosteroids, B-cell or plasma-cell therapies, complement-directed treatment, or other center-specific approaches. Evidence for many regimens remains limited, especially in chronic active AMR.
Do not change immunosuppressive medicine without the transplant team. Reducing or stopping treatment can rapidly increase immune risk, while adding medication without supervision can cause serious infection, cancer, kidney injury, low blood counts, and other toxicity.
Track results as a timeline rather than isolated numbers. Record the sample date, DSA target, MFI or titer, medication levels, graft-function measures, biopsies, treatments, and sensitizing events. A well-organized history helps clinicians recognize whether an antibody is new, persistent, recurrent, or responding to treatment.
A DSA result is most useful when it changes a specific action: donor selection, compatibility planning, surveillance intensity, biopsy timing, adherence support, or treatment. The transplant team and histocompatibility laboratory should interpret it together.
References
- Association of donor-specific antibodies with adverse outcomes in solid organ transplantation: A systematic review and meta-analysis of 69 studies 2025 (Systematic Review)
- ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies 2024 (Consensus)
- European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study 2024 (Consensus)
- The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice 2023 (Consensus)
- Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document 2023 (Consensus)
- Complement-activating donor-specific anti-HLA antibodies in solid organ transplantation: systematic review, meta-analysis, and critical appraisal 2023 (Systematic Review)
Disclaimer
This article provides general information and cannot interpret an individual transplant result. DSA findings should be reviewed by the transplant team and histocompatibility laboratory alongside donor typing, crossmatch, medication history, graft function, and biopsy results. Contact the transplant team promptly for new symptoms or a sudden change in organ function.
